Oculis’ Post

It's a privilege to appear with other Alberta #healthtech #entrepreneurs in 2023's final edition of Disruption, titled "For our Health". The issue focuses on those disrupting the healthcare space with technologies that hold immense potential for pushing the status quo and seeing results in patient health. Among the others featured are: -a portable tissue imaging technology for more timely use and better outcomes -wearable tech that uses biometrics to let users take control of their health -a more accurate and less invasive test for prostate cancer Also read about the investors who back them, who step up to make it real, and who help to bring these new innovations towards their intended use.

Are you attending the Sept. 25th San Francisco #AdvancedTherapiesXchange? Drawing on his 30+ years of experience leading immune cell operations, Kevin King, Senior Director of #CellandGeneTherapy Strategy and Growth at BioIVT, will be leading the 11:25am session “From Donor to Development: Minimizing Risks in the Cell Starting Materials Supply Chain” discussing strategies to de-risk the utilization of cellular starting and raw materials in the manufacture of #AdvancedTherapies: https://hubs.ly/Q02Qbz6B0 In the absence of industry-wide standardization of human cells, tissues, and cellular and tissue-based products (HCT/Ps), production and manufacturing processes are not equivalent among suppliers. This can create significant efficiency, quality and regulatory obstacles as therapeutic platforms transition from preclinical to clinical application. Kevin will also be joined by Lisa Kretzschmar, Senior Scientific Advisor for CGT at BioIVT, and Adam Ross, Technical Sales Specialist for CGT at BioIVT, for 1:1 meeting requests to discuss: - Why you need a partner that can take you from RUO to GMP - The value of having a geographically expansive, secure supply chain - The importance of donor diversity and its impact on your success - How BioIVT can support your CGT development, from discovery to clinical development Make sure to connect with our expert team if you’d like to schedule a meeting! Learn more about our CGT solutions: https://hubs.ly/Q02QbVwK0 #CellTherapy #GeneTherapy #ATMPs #hubXchange

The #biopharmaceutical industry stands at a pivotal juncture! Some of the common challenges are unstructured data, resistance to change, data silos, and shadow silos. Learn to overcome these and thrive in an era of data-driven innovation 👉 https://lnkd.in/ehbYsy8U #biotech #semanticsearch #semanticdiscoveryplatform #WisecubeAI

If you have clinician colleagues who need CME or you are curious about DTx, check out our introductory course!

🚨 Acticor Biotech: Strategic Appointment and Clinical Developments! 🚨   We are sharing two major updates for Acticor Biotech :  🔹 Clinical Focus: Acticor Biotech is preparing the design for an upcoming GLORIA clinical trial, aimed at assessing glenzocimab's benefits in angioplasty for STEMI. Currently, 27 patients have been enrolled in the Phase 2b LIBERATE study, evaluating our innovative drug, glenzocimab, in the treatment of ST-Elevation Myocardial Infarction (STEMI).  🔗 : https://lnkd.in/edRtDvhX 🔹 Francois Guillet has been appointed as Chief Financial Officer. With his extensive experience in restructuring and international management, François will be a valuable asset in guiding Acticor Biotech through this strategic phase. We are thankful to Eric COHEN for his remarkable contributions since 2016, especially during Acticor's IPO. 🔗 : https://lnkd.in/ej3Y4Ukc #Biotech #innovation #clinicaldevelopment

Interesting clip (and a link to a full length webinar) on #MedPharm's 3D nasal cast model! #nasaldelivery #nasalformulationdevelopment

Avidity Biosciences, Inc. which received early funding from CureDuchenne, announced positive initial data from their EXPLORE44 Trial for individuals with Duchenne amenable to skipping exon 44. Their experimental exon-skipping agent, AOC 1044 (del-zota), at 5 mg/kg increased exon 44 skipping by an average of 37% (from 7% at baseline to 44%) and increased average dystrophin levels by 25% (from 7% of normal at baseline to 32%) after 3 doses received once every 6 weeks. Creatine kinases levels were reduced to near normal levels. Register for the webinar on August 16, 2024, at 9 AM PST: https://lnkd.in/gEEhp-kc Learn more and read the letter to the community: https://lnkd.in/gq562NU7 #DMD #duchenne #exonskipping #CureDuchenne #AvidityBioscience #FDA #clinicaltrials

🌟 Exciting Growth in the Global Near Infrared Imaging Market! 🌟 The Global Near Infrared (NIR) Imaging Market is set to expand at a robust growth rate of 7-8% over the next five years. Explore more market insights and trends with our detailed analysis: https://lnkd.in/dUuxhuzy Key players shaping the NIR landscape include Thermo Fisher Scientific, Inc., Merck KGaA, Agilent Technologies, Inc., CRISPR Therapeutics AG, Genscript Biotech Corporation, Lonza Group, Ltd., PerkinElmer, Inc., Caribou Biosciences, Inc., Hera Biolabs, and OriGene Technologies, Inc. As we look ahead, the future of NIR imaging is bright, promising improved patient outcomes and revolutionary advancements in medical imaging. 🌐🔬 #NearInfraredImaging #MedicalImaging #HealthcareInnovation #NIRTechnology #ChronicDiseaseManagement #SurgicalAdvancements #HealthcareGrowth #MedicalResearch #FutureOfImaging #HealthcareTech #MedicalTechnology #HealthcareIndustry #ImagingTechnology #NIRImaging #SurgicalInnovation #AdvancedImaging #MedicalDevices #TechInHealthcare #HealthcareResearch #GlobalHealth #MedicalAdvancements #HealthcareSolutions #InnovationInHealthcare #ChronicDiseaseCare #MedicalTechTrends #HealthcareMarket #NIRImagingGrowth #RegulatorySupport #SurgicalProcedures #ImagingSolutions

🌟 Exciting Growth in the Global Near Infrared Imaging Market! 🌟 The Global Near Infrared (NIR) Imaging Market is set to expand at a robust growth rate of 7-8% over the next five years. Explore more market insights and trends with our detailed analysis: https://lnkd.in/dUuxhuzy Key players shaping the NIR landscape include Thermo Fisher Scientific, Inc., Merck KGaA, Agilent Technologies, Inc., CRISPR Therapeutics AG, Genscript Biotech Corporation, Lonza Group, Ltd., PerkinElmer, Inc., Caribou Biosciences, Inc., Hera Biolabs, and OriGene Technologies, Inc. As we look ahead, the future of NIR imaging is bright, promising improved patient outcomes and revolutionary advancements in medical imaging. 🌐🔬 #NearInfraredImaging #MedicalImaging #HealthcareInnovation #NIRTechnology #ChronicDiseaseManagement #SurgicalAdvancements #HealthcareGrowth #MedicalResearch #FutureOfImaging #HealthcareTech #MedicalTechnology #HealthcareIndustry #ImagingTechnology #NIRImaging #SurgicalInnovation #AdvancedImaging #MedicalDevices #TechInHealthcare #HealthcareResearch #GlobalHealth #MedicalAdvancements #HealthcareSolutions #InnovationInHealthcare #ChronicDiseaseCare #MedicalTechTrends #HealthcareMarket #NIRImagingGrowth #RegulatorySupport #SurgicalProcedures #ImagingSolutions